Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 5, 2012, Pages 837-842

  Liu, Jieqiong ^a   Deng, Heran ^a   Jia, Weijuan ^a   Zeng, Yunjie ^a   Rao, Nanyan ^a   Li, Shunrong ^a   Jin, Liang ^a   Wu, Jiannan ^a   Song, Erwei ^a   Su, Fengxi ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Breast cancer; ER; HER2; Liver metastasis; PR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PARTIAL MASTECTOMY; POSTOPERATIVE CARE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR VOLUME; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; CHEMORADIOTHERAPY; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; SECONDARY; SEGMENTAL MASTECTOMY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; CHEMORADIOTHERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84863088603     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1150-1     Document Type: Article

References (26)

1. Bozzetti C, Personeni N, Nizzoli R, Guazzi A, Flora M, Bassano C, Negri F, Martella E, Naldi N, Franciosi V, Cascinu S (2003) HER-2/neu amplification by Xuorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer 99:310-315 (Pubitemid 37248379)
2. Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, Gardini G, Nizzoli R, Leonardi F, Gasparro D et al (2011) Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 104:1372-1376
3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502 (Pubitemid 43854964)
4. Egeblad M, Nakasone ES, Werb Z (2010) Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18:884-901
5. Fabi A, Di Benedetto A, Metro G, Perracchio L, Nistico C, Di Filippo F, Ercolani C, Ferretti G, Melucci E, Buglioni S et al (2011) HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 17:2055-2064
6. Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordon-Cardo C, Olshen AB, Gerald WL, Massague J (2005) Identifying sitespecific metastasis genes and functions. Cold Spring Harb Symp Quant Biol 70:149-158 (Pubitemid 44124866)
7. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
8. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481 (Pubitemid 29220854)
9. Jensen JD, Knoop A, Ewertz M, Laenkholm AV (2011) ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer. Breast Cancer Res Treat [Epub ahead of print]
10. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11:R31
11. Linos E, Spanos D, Rosner BA, Linos K, Hesketh T, Qu JD, Gao YT, Zheng W, Colditz GA (2008) EVects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer Inst 100:1352-1360
12. Masood S, Bui MM (2000) Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 30:259-265 (Pubitemid 30620800)
13. McDermott SP, Wicha MS (2010) Targeting breast cancer stem cells. Mol Oncol 4:404-419
14. Niehans GA, Singleton TP, Dykoski D, Kiang DT (1993) Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 85:1230-1235 (Pubitemid 23223529)
15. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez- Boussard T, Livasy C, Cowan D, Dressler L et al (2004) Immunohistochemical and clinical characterization of the basallike subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374 (Pubitemid 39100473)
16. Pentheroudakis G, Fountzilas G, Bafaloukos D, Koutsoukou V, Pectasides D, Skarlos D, Samantas E, Kalofonos HP, Gogas H, Pavlidis N (2006) Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat 97:237-244 (Pubitemid 43945754)
17. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
18. Pusztai L, Viale G, Kelly CM, Hudis CA (2010) Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist 15:1164-1168
19. Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39-51
20. Satti MB (2011) Oestrogen receptor/progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer: a 9- year study at Princess Noorah Oncology Center, Saudi Arabia. Histopathology
21. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874 (Pubitemid 32878711)
22. St Romain P, Madan R, Tawfik OW, Damjanov I, Fan F (2011) Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or Wction? A clinicopathologic analysis. Hum Pathol [Epub ahead of print]
23. Talmadge JE, Fidler IJ (2010) AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 70:5649-5669
24. Tapia C, Savic S, Wagner U, Schonegg R, Novotny H, Grilli B, Herzog M, Barascud AD, Zlobec I, Cathomas G et al (2007) HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 9:R31
25. Vincent-Salomon A, Jouve M, Genin P, Freneaux P, Sigal-Zafrani B, Caly M, Beuzeboc P, Pouillart P, Sastre-Garau X (2002) HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 94:2169-2173 (Pubitemid 34411973)
26. Vincent-Salomon A, Pierga JY, Couturier J, d'Enghien CD, Nos C, Sigal-Zafrani B, Lae M, Freneaux P, Dieras V, Thiery JP, Sastre- Garau X (2007) HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? Br J Cancer 96:654-659